Ethics approval and consent to participate
CM
The study was approved by the Ethics Committee of Zhongshan Hospital (Number B2021–360) and was registered with the Chinese Clinical Trial Registry prior to patient enrollment (ChiCTR2100048904; Principal investigator: CM; Date of registration: July 19, 2021). The trial was modified on September 23, 2021 to add an additional arm to test RT + flumazenil. Patients were recruited from October 2021 to December 2021 at Zhongshan Hospital Fudan University, Shanghai, China. Written informed consent was obtained from all participants included in the study. This manuscript adheres to the applicable Consolidated Standards of Reporting Trials guidelines. All methods were carried out in accordance with relevant guidelines and regulations.